Home
Storia in 1 fonti
Fierce Pharma Asia—Historic solid tumor CAR-T nod; Inside Pfizer, Innovent’s $10B pact; More China deals
In the past two weeks, CARsgen Therapeutics won the world's first regulatory approval for a solid tumor CAR-T, a behind-the-scenes look at Pfizer and Innovent Biologics' $10.5 billion cancer deal r | In the past two weeks, CARsgen won the world's first approval for a solid tumor CAR-T, a behind-the-scenes look at Pfizer and Innovent Biologics' $10.5 billion cancer deal revealed a less-than-five-month sprint, Daiichi Sankyo's new R&D chief discussed how he plans to keep the antibody-drug conjugate leader ahead in the game, and a flurry of China licensing deals with various structures have emerged.
Raccontata da
fiercepharma.com
Timeline cronologica
- ·
Big obesity bets and China's rise fuel potential $2T in 2032 drug sales: Evaluate
While dealmaking and investment dollars may be flowing across biopharma once again, acute challenges tied to policy, pricing and more continue to dog the industry, even as…
- ·
Pfizer scores 1st expansion in 7 years for breast cancer blockbuster Ibrance
It’s been seven years since Pfizer scored an expansion for its breast cancer blockbuster Ibrance, and during that time, the drug has started to lag sales of two others in its…
- ·
Fosun Pharma plots global push beyond oncology, fueled by multi-asset Alzheimer’s strategy
Driven by personal losses, major unmet needs and a desire to diversify from the crowded oncology market, Fosun Pharma is making high-stakes bets in neurodegenerative diseases to…
- ·
Fierce Pharma Asia—Historic solid tumor CAR-T nod; Inside Pfizer, Innovent’s $10B pact; More China deals
In the past two weeks, CARsgen Therapeutics won the world's first regulatory approval for a solid tumor CAR-T, a behind-the-scenes look at Pfizer and Innovent Biologics' $10.5…
- ·
Europe's CHMP reverses endorsement of Amgen's Tavneos as FDA hearing looms
As Amgen prepares to defend Tavneos’ market approval in the U.S., the company has received a bad omen overseas, with regulators recommending that the ANCA-associated vasculitis…